Overview

* Sonoma fiscal Q1 revenue rises 18% yr/yr, missing analyst expectations

* U.S. revenue increases 57% due to higher health care product sales

* Net loss per share for fiscal Q1 decreased 43% yr/yr

Result Drivers

* U.S. REVENUE GROWTH - 57% increase in U.S. revenue driven by higher sales of human and animal health care products

* STRATEGIC INITIATIVES - Expansion of consumer-focused product portfolio and regulatory approvals contributed to revenue growth

* LATIN AMERICA DECLINE - Revenue decreased due to timing of customer orders for overflow manufacturing

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q1 Miss $4 mln $4.05

Revenue mln (1

Analyst)

Q1 Gross $1.50

Profit mln

Q1 $2.60

Operatin mln

g

Expenses

Analyst Coverage

* The one available analyst rating on the shares is "strong buy"

* The average consensus recommendation for the pharmaceuticals peer group is "buy."

* Wall Street's median 12-month price target for Sonoma Pharmaceuticals Inc ( SNOA ) is $14.80, about 79.6% above its August 6 closing price of $3.02

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)